Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04455919
Other study ID # PAP/RI2/2019_05
Secondary ID 2019-A01632-55
Status Terminated
Phase N/A
First received
Last updated
Start date October 3, 2019
Est. completion date March 30, 2020

Study information

Verified date July 2020
Source Centre Hospitalier Universitaire de Pointe-a-Pitre
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the benefits of a 8-week yoga program on quality of life in patients suffering from chronic chikungunya.

Studies have already shown the effectiveness of yoga practice on various arthralgia's, on the reduction of inflammatory reactions, on psychological disorders/sleep disorders and on quality of life. Considering quality of life as a global experience of balance between physical and mental wellbeing, the hypothesis was that the practice of yoga would globally improve the quality of life of patients with chronic chikungunya.


Description:

The chikungunya virus (CHIKV) is an arbovirus passed to humans by Aedes mosquitoes. Since its description in 1952, CHIKV has caused millions of human infections in Africa, the Indian Ocean islands, Asia, Europe and America (1). In total, since 2013, the epidemic has affected more than 2 million people in the Americas. In Guadeloupe, the emergence of chikungunya cases began in 2013. CHINKV was declared an epidemic in 2014 with an estimated 20,000 infected patients.Human infection with CHIKV is characterized by a sudden onset of severe joint pains, high fever and rash. The infection is self-limited and acute symptoms usually disappear within one or two weeks. However, this polyarthralgia is recurrent in 30 to 40% of infected people and can persist for years. Chikungunya is considered chronic if the symptoms persist after three months. The chronic stage can last from a few months to several years. Chronic chikungunya usually manifests as joint pain and stiffness, polyarthralgia (including rheumatoid arthritis, flare-ups of spondylitis), and other general symptoms such as intermittent headaches, edema, and paresthesia. The consequences of chronic CHIKV can be severe, with patients becoming maladjusted to their lifestyle, feeling weakened and diminished. Depression and medical leaves are very frequent, with many cases of disability. Yoga is an ancestral Indian practice aiming to connect the "body" and the "soul", the "self" and "the other". Traditionally, it is a philosophical way of living, sometimes combined with the practice of physical exercises. In westernized countries, Yoga is usually considered as a physical practice or an alternative therapy, using various techniques of breathing, relaxation and poses to release tensions and decrease pain.

Studies have already shown the effectiveness of yoga practice on various arthralgia's, on the reduction of inflammatory reactions, on psychological disorders/sleep disorders and on quality of life. Considering quality of life as a global experience of balance between physical and mental wellbeing, the hypothesis was that the practice of yoga, by improving these different aspects, would globally improve the quality of life of patients with chronic chikungunya.


Recruitment information / eligibility

Status Terminated
Enrollment 42
Est. completion date March 30, 2020
Est. primary completion date March 30, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- Patients suffering from chronic chikungunya, as documented by a positive chikungunya serology and the following symptoms: polyarthralgia and/or musculoskeletal disorder and/or morning stiffness.

- Patients had to be between 18 and 70 years old, and be

- patients affiliated to the French social insurance.

Exclusion Criteria:

- being pregnant;

- suffering from pre-existing rheumatic diseases before the Chikungunya infection;

- showing acute symptoms of a Chikungunya infection (documented serology);

- being unable to practice yoga poses ; having been recently treated with methotrexate or corticosteroids (less than 3 months ago);

- being under guardianship, trusteeship or legal protection,

- participating in another research study,

- showing severely impaired physical and/or psychological health, which in the opinion of the investigator, may affect the compliance of the study participant.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Wait-list group
The wait-list group benefit from a 8-week yoga program after the interventional group
Yoga group
During 8 weeks, the intervention group attended weekly yoga sessions and had to practice poses at home

Locations

Country Name City State
Guadeloupe Mouffias' Medical Center in Guadeloupe. Pointe-à-Pitre

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire de Pointe-a-Pitre

Country where clinical trial is conducted

Guadeloupe, 

Outcome

Type Measure Description Time frame Safety issue
Primary Health Related Quality of Life - Short Form-36 (SF-36) This scale measures eight health domains (Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, Mental Health) of quality of life for adults aged 18 and older. Using a scoring algorithm, the aggregated scores can provide two summary scores: the physical component summary (PCS) score and the mental component summary (MCS) score. At baseline
Primary Health Related Quality of Life - Short Form-36 (SF-36) This scale measures eight health domains (Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, Mental Health) of quality of life for adults aged 18 and older. Using a scoring algorithm, the aggregated scores can provide two summary scores: the physical component summary (PCS) score and the mental component summary (MCS) score. after 8 weeks of intervention
Primary Health Related Quality of Life - Short Form-36 (SF-36) This scale measures eight health domains (Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, Mental Health) of quality of life for adults aged 18 and older. Using a scoring algorithm, the aggregated scores can provide two summary scores: the physical component summary (PCS) score and the mental component summary (MCS) score. after 18 weeks
Secondary nociceptive pain - Visual Analog Scale (VAS) The Visual Analog Scale (VAS) is a 10 cm line with anchor statements on the left (no pain) and on the right (extreme pain). The patient is asked to mark their current pain level on the line. They can also be asked to mark their maximum, minimum, and average pain. The examiner scores the VAS by measuring the distance in either centimeters (0 to 10) or millimeters (0 to 100) from the "no pain" anchor point. At baseline
Secondary nociceptive pain - Visual Analog Scale (VAS) The Visual Analog Scale (VAS) is a 10 cm line with anchor statements on the left (no pain) and on the right (extreme pain). The patient is asked to mark their current pain level on the line. They can also be asked to mark their maximum, minimum, and average pain. The examiner scores the VAS by measuring the distance in either centimeters (0 to 10) or millimeters (0 to 100) from the "no pain" anchor point. after 8 weeks of intervention
Secondary nociceptive pain - Visual Analog Scale (VAS) The Visual Analog Scale (VAS) is a 10 cm line with anchor statements on the left (no pain) and on the right (extreme pain). The patient is asked to mark their current pain level on the line. They can also be asked to mark their maximum, minimum, and average pain. The examiner scores the VAS by measuring the distance in either centimeters (0 to 10) or millimeters (0 to 100) from the "no pain" anchor point. after 18 weeks
Secondary neuropathic pain- DN4 scale The total score is calculated as the sum of the 10 items and the cut-off value for the diagnosis of neuropathic pain is a total score of 4/10. At baseline
Secondary neuropathic pain- DN4 scale The total score is calculated as the sum of the 10 items and the cut-off value for the diagnosis of neuropathic pain is a total score of 4/10. after 8 weeks of intervention
Secondary neuropathic pain- DN4 scale The total score is calculated as the sum of the 10 items and the cut-off value for the diagnosis of neuropathic pain is a total score of 4/10. after 18 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT02230163 - Clinical Evaluation of Anti-CHIKV Hyperimmune Intravenous Immunoglobulins Phase 1/Phase 2
Completed NCT04546724 - Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults Phase 3
Completed NCT03631719 - Impact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, Colombia
Active, not recruiting NCT04441905 - Phase 1 Study of SAR440894 vs Placebo Phase 1
Completed NCT02562482 - Trial for Safety and Immunogenicity of a Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults Phase 2
Completed NCT03028441 - Phase I Trial of Measles Vectored Chikungungya Vaccine Phase 1
Completed NCT03807843 - Chikungunya Vaccine (V184) Study in Previously Exposed Adults (V184-006) Phase 2
Completed NCT04909411 - Consequences of a Maternal-fetal Chikungunya Virus Infection N/A
Completed NCT04786444 - Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy Adults Phase 3
Completed NCT02553369 - Seroprevalence of Chikungunya at the End of the First Chikungunya Outbreak in the French Antilles Within a Sample of Patients Treated for a HIV Infection N/A
Recruiting NCT06106581 - A Phase 2 Clinical Study of VLA1553 in Healthy Children Aged 1 to 11 Years Phase 2
Recruiting NCT06007183 - Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination Phase 3
Completed NCT03635086 - Safety, Tolerability and Long-term Immunogenicity of Different Formulations of a Chikungunya Vaccine (V184-005) Phase 2
Completed NCT02861586 - Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine Phase 2
Active, not recruiting NCT04838444 - Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine Candidate (VLA1553) Phase 3
Completed NCT03483961 - Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults Phase 2
Recruiting NCT06028841 - A Clinical Phase 3 Study of VLA1553 in Adult Participants With Human Immunodeficiency Virus (HIV) Phase 3